Global Diabetic Gastroparesis Treatment Market Report and Forecast 2023-2031

Global Diabetic Gastroparesis Treatment Market Report and Forecast 2023-2031

Global Diabetic Gastroparesis Treatment Market Outlook:

The global diabetic gastroparesis treatment market value was USD 3.5 billion in 2022, driven by the increasing prevalence of diseases across the globe. The market size is anticipated to grow at a CAGR of 4.1% during the forecast period of 2023-2031 to achieve a value of USD 5 billion by 2031.

Diabetic Gastroparesis Introduction

Diabetic gastroparesis refers to a condition characterized by delayed gastric emptying in individuals with diabetes. It occurs due to nerve damage in the stomach, resulting in symptoms such as nausea, vomiting, bloating, and abdominal pain. Effective treatment of diabetic gastroparesis aims to manage symptoms, improve gastric emptying, and enhance overall quality of life for affected individuals.

Key Trends in the Diabetic Gastroparesis Treatment Market

Some of the key trends in the market are:

Pharmacological Advancements: The treatment of diabetic gastroparesis has seen notable advancements in pharmacological options. Prokinetic agents, such as metoclopramide and domperidone, are commonly prescribed to enhance gastric motility. Additionally, newer medications, such as ghrelin agonists and gastric peroral endoscopic pyloromyotomy (G-POEM), are being studied and show promise in managing gastroparesis symptoms.
Dietary Modifications: Dietary adjustments play a crucial role in managing diabetic gastroparesis. Key trends include the adoption of a low-fat, low-fiber diet consisting of smaller and more frequent meals. Individuals may also benefit from a dietitian's guidance to customize their dietary plan based on their specific needs and symptoms. Moreover, the use of nutritional supplements, including liquid meal replacements, may be recommended to ensure adequate nutrition.
Emerging Therapies and Procedures: Advancements in medical technology have led to the emergence of alternative therapies and procedures for diabetic gastroparesis. These include gastric electrical stimulation (GES), which involves implanting a device to deliver electrical impulses to the stomach to improve motility. Other minimally invasive procedures, such as endoscopic pyloroplasty, are being explored as potential treatment options.
Multidisciplinary Approach: The management of diabetic gastroparesis often requires a multidisciplinary approach involving healthcare professionals from various fields. This may include endocrinologists, gastroenterologists, dietitians, and psychologists, who collaborate to provide comprehensive care. Such an approach ensures that patients receive individualized treatment plans tailored to their specific needs and addresses the various aspects of the condition.

Diabetic Gastroparesis Treatment Market Segmentations

Market Breakup by Type

Surgical Treatment Products
Drugs
Market Breakup by Disease Indication

Compensated Gastroparesis
Gastric Failure
Others
Market Breakup by End User

Hospitals
Specialty Clinics
Homecare
Market Breakup by Route of Administration

Oral
Injectables
Market Breakup by Region

North America
United States of America
Canada
Europe
United Kingdom
Germany
France
Italy
Others
Asia Pacific
China
Japan
India
ASEAN
Australia
Others
Latin America
Brazil
Argentina
Mexico
Others
Middle East and Africa
Saudi Arabia
United Arab Emirates
Nigeria
South Africa
Others

Diabetic Gastroparesis Treatment Market Scenario

The market for diabetic gastroparesis treatment is driven by the growing prevalence of diabetes and the subsequent increase in the number of individuals affected by gastroparesis. Diabetic gastroparesis treatment aims to alleviate symptoms, improve gastric emptying, and enhance the overall quality of life for patients.

The market is characterized by a range of treatment options, including pharmacological interventions, dietary modifications, and emerging therapies. Pharmacological advancements have resulted in the availability of prokinetic agents that promote gastric motility and reduce symptoms. Additionally, there is ongoing research on novel medications and therapies, such as ghrelin agonists and gastric electrical stimulation, which show potential for improving gastric function and symptom management.

Dietary modifications play a significant role in managing diabetic gastroparesis, leading to a demand for specialized diets and nutritional supplements. The market offers low-fat, low-fiber dietary recommendations, as well as liquid meal replacements to ensure adequate nutrition. Dietary guidelines are often tailored to individual needs, and the availability of dietary counseling and support services further drives the market growth.

As the awareness and diagnosis of diabetic gastroparesis improve, the market is expected to witness substantial growth. The increasing prevalence of diabetes, coupled with the demand for more effective and personalized treatment options, drives the market expansion. Furthermore, the focus on patient education, support services, and the establishment of patient advocacy groups contribute to the growth of the market.

Diabetic Gastroparesis Treatment Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Evoke Pharma Inc.
Allergen Pnc.
Salix Pharmaceuticals
Theravance Biopharma Inc.
Medtronics pLC
Abbot
Rhythm Pharmaceuticals
Allergen plc.
Astrazeneca plc.
Cadila Pharmaceuticals
Neurogastrx Inc
Bausch Health